|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Cefazolin** | **Cefazolin + Metronidazole** | **Other** | **p-value** |
| N | 163,210 | 9504 | 69,635 |  |
| Age | 43 (37-48) | 44 (38-50) | 43 (37-49) | <0.001 |
| Age <50 | 82% (133,164) | 76% (7219) | 80% (55,710) | <0.001 |
| RaceWhiteBlackHispanicOther/unknown | 70% (114,300)14% (22,698)7.5% (12,194)8.6% (14,018) | 65% (6158)18% (1693)7% (661)10% (992) | 74% (51,675)11% (7654)5.1% (3564)9.7% (6742) | <0.001 |
| InsuranceCommercialManaged CareMedicaidMedicareOtherSelf-Pay | 14% (23,026)54% (88,710)16% (26,248)7.2% (11,740)5.7% (9307)2.6% (4179) | 20% (1892)43% (4096)20% (1863)10% (962)4.3% (407)3% (284) | 14% (9529)52% (36,488)18% (12,569)8.6% (5975)5.3% (3694)2% (1380) | <0.001 |
| Hysterectomy RouteAbdominalLAVHLaparoscopicRoboticVaginal | 3.4% (5575)44% (71,489)37% (61,150)5.9% (9628)9.4% (15,368) | 2.2% (212)37% (3540)47% (4426)8.4% (799)5.5% (527) | 4.1% (2860)47% (32,473)35% (24,588)5.5% (3815)6.5% (5899) | <0.001 |
| Obesity | 18% (28,801) | 25% (2341) | 18% (12,766) | <0.001 |
| Tobacco Use | 25% (41,451) | 31% (2926) | 29% 19,968) | <0.001 |
| MRSA colonization | 0.048% (79) | 0.021% (2) | 0.089% (62) | <0.001 |
| Penicillin Allergy | 2.1% (3381) | 2.5% (242) | 12% (8525) | <0.001 |
| Diabetes without complication | 5.2% (8546) | 5.2% (491) | 6.3% (4389) | <0.001 |
| Diabetes with complication | 0.71% (1160) | 1.4% (130) | 0.84% (585) | <0.001 |
| Charlson Comorbidity Index | 0.6 (1.1) | 0.8 (1.3) | 0.7 (1.1) | <0.001 |
| Urban location | 86% (140,557) | 88% (8339) | 83% (58,043) | <0.001 |
| Teaching hospital | 34% (55,341) | 38% (3592) | 34% (23,969) | <0.001 |
| SSI 0-3 m | 2.1% (3492) | 1.9% (180) | 2.7% (1846) | <0.001 |
| SSI 0-12 m | 2.8% (4559) | 2.4% (229) | 3.4% (2364) | <0.001 |
| Readmission 0-3 m | 4% (6600) | 3.7% (347) | 4.5% (3166) | <0.001 |
| ER visit 0-3 m | 15% (23,814) | 14% (1304) | 15% (10,187) | 0.06 |